Novartis to acquire Fougera Pharmaceuticals in USD1.525bn all-cash deal
Novartis has signed a definitive agreement to acquire specialty dermatology generics company Fougera Pharmaceuticals. Under the terms of the agreement, Novartis will acquire the business, which is based in Melville, New York, for USD1.525 billion in an all-cash transaction. The sellers are comprised of a consortium of private equity
